Abstract

Our goal is to continue to perform high quality phase I, II, and III clinical trials evaluating new drugs against HIV and the opportunistic infections and neoplasms complicating this disease. This will be accomplished by maintaining our experienced and dedicated staff of physicians, nurses, data managers and laboratory personnel so that they can continue to enroll patients into clinical trials from all of New York, but especially from Bellevue Hospital. Patients will be seen in the General Clinical Research Center for both in- patient phase I and out-patient studies. Virology and pharmacology will be performed in our Core laboratories. In addition, we will perform immunological and virological research that is directly associated with the clinical trials. Our enrollment of patients into trials will be increased significantly by our subunit at nearby Cabrini Medical Center where large numbers of HIV infected individuals receive their primary care.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI027665-08
Application #
2063990
Study Section
Special Emphasis Panel (SRC (45))
Project Start
1986-06-30
Project End
1995-12-31
Budget Start
1994-01-01
Budget End
1994-12-31
Support Year
8
Fiscal Year
1994
Total Cost
Indirect Cost

  Institution

Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
New York
State
NY
Country
United States
Zip Code
10012

  Publications

Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Gupta, S K; Kitch, D; Tierney, C et al. (2015) Markers of renal disease and function are associated with systemic inflammation in HIV infection. HIV Med 16:591-8
Longenecker, Chris T; Kitch, Douglas; Sax, Paul E et al. (2015) Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr 69:168-77
Gupta, Samir K; Kitch, Douglas; Tierney, Camlin et al. (2014) Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial. Open Forum Infect Dis 1:ofu003
Erlandson, Kristine Mace; Kitch, Douglas; Tierney, Camlin et al. (2014) Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS 28:1451-61
Wyatt, Christina M; Kitch, Douglas; Gupta, Samir K et al. (2014) Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr 67:36-44
Safren, Steven A; Biello, Katie B; Smeaton, Laura et al. (2014) Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One 9:e104178
McComsey, Grace A; Kitch, Douglas; Sax, Paul E et al. (2014) Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr 65:167-74
Erlandson, Kristine M; Kitch, Douglas; Tierney, Camlin et al. (2013) Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS 27:2069-79
Gandhi, Rajesh T; Bosch, Ronald J; Aga, Evgenia et al. (2013) Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173. Antivir Ther 18:607-13

Showing the most recent 10 out of 103 publications